| Literature DB >> 30725173 |
Thomas G Papathomas1,2, Na Sun2, Vasileios Chortis1,3, Angela E Taylor1,3, Wiebke Arlt1,3, Susan Richter4,5, Graeme Eisenhofer4,5,6, Gerard Ruiz-Babot6,7,8, Leonardo Guasti8, Axel Karl Walch9.
Abstract
Metabolic alterations have implications in a spectrum of tissue functions and disease. Aided by novel molecular biological and computational tools, our understanding of physiological and pathological processes underpinning endocrine and endocrine-related disease has significantly expanded over the last decade. Herein, we focus on novel metabolomics-related methodologies in adrenal research: in situ metabolomics by mass spectrometry imaging, steroid metabolomics by gas and liquid chromatography-mass spectrometry, energy pathway metabologenomics by liquid chromatography-mass spectrometry-based metabolomics of Krebs cycle intermediates, and cellular reprogramming to generate functional steroidogenic cells and hence to modulate the steroid metabolome. All four techniques to assess and/or modulate the metabolome in biological systems provide tremendous opportunities to manage neoplastic and non-neoplastic disease of the adrenal glands in the era of precision medicine. In this context, we discuss emerging clinical applications and/or promising metabolic-driven research towards diagnostic, prognostic, predictive and therapeutic biomarkers in tumours arising from the adrenal gland and extra-adrenal paraganglia as well as modern approaches to delineate and reprogram adrenal metabolism.Entities:
Keywords: Adrenal glands; Cellular reprogramming; In situ metabolomics; Metabologenomics; Steroid metabolomics
Mesh:
Year: 2019 PMID: 30725173 DOI: 10.1007/s00418-019-01772-w
Source DB: PubMed Journal: Histochem Cell Biol ISSN: 0948-6143 Impact factor: 4.304